Kisspeptin and Sexual Arousal: The Brain Data
Kisspeptin
56% increase
Kisspeptin-54 infusion increased penile tumescence by up to 56% compared to placebo in men with hypoactive sexual desire disorder, alongside enhanced sexual brain processing on fMRI.
Mills et al., JAMA Network Open, 2023
Mills et al., JAMA Network Open, 2023
View as imageKisspeptin is best known as the upstream switch for GnRH and reproductive hormones. But research over the past decade has revealed a second, distinct role: kisspeptin directly activates brain circuits involved in sexual arousal, attraction, and desire. This is not a downstream hormonal effect. The brain changes occur on a timescale of minutes, before any measurable change in testosterone or LH. As the pillar article on kisspeptin outlines, this peptide operates at the intersection of reproduction and desire. This article covers the specific fMRI evidence.
Key Takeaways
- In healthy men, kisspeptin-54 enhanced limbic brain activity in response to sexual images, with increased activation in the anterior cingulate, putamen, and thalamus[1]
- In men with HSDD, kisspeptin increased penile tumescence by up to 56% versus placebo and significantly modulated sexual brain processing (Cohen d = 0.81)[2]
- In women with HSDD, kisspeptin reduced activity in brain regions associated with sexual aversion and negative self-focus, and increased self-reported feelings of being "sexy"[3]
- Kisspeptin also enhanced brain responses to non-sexual cues of attraction, including female olfactory cues, in healthy men[4]
- KISS1R receptors are expressed in limbic brain regions (amygdala, hippocampus, cingulate cortex) beyond the hypothalamic reproductive centers[5]
- These effects occur within minutes of kisspeptin administration, faster than any hormonal pathway could explain, indicating direct neural action
The Landmark Study: Healthy Men (2017)
Comninos et al. (2017) published the first evidence that kisspeptin affects sexual brain processing in humans[1]. The study enrolled 29 healthy heterosexual men in a randomized, double-blind, placebo-controlled crossover design. Each participant received both kisspeptin-54 (1 nmol/kg/h IV infusion) and matched placebo, separated by a washout period, while undergoing functional MRI.
During kisspeptin infusion, participants viewed sexual images, non-sexual couple-bonding images, and neutral images. The results were striking:
Sexual stimuli: Kisspeptin enhanced activity in the anterior cingulate cortex, posterior cingulate cortex, putamen, globus pallidus, and thalamus. These regions form the core sexual-processing network in the human brain.
Couple-bonding stimuli: Kisspeptin also enhanced limbic responses to non-sexual romantic images, suggesting it modulates broader pair-bonding circuitry, not just sexual arousal.
Negative emotional stimuli: Kisspeptin attenuated negative mood responses on validated psychometric scales, suggesting an anxiolytic or mood-enhancing component to its effects.
The timing was critical. Brain changes appeared within 15-30 minutes of starting the infusion. LH levels did increase, but the sexual brain effects did not correlate with LH changes. This dissociation between hormonal and neural effects suggests kisspeptin acts directly on KISS1R in limbic brain regions, independently of its reproductive hormone effects.
The study also measured psychometric outcomes using validated scales. Kisspeptin reduced negative mood scores and enhanced responses on measures of sexual arousal. These behavioral effects, combined with the fMRI data, established for the first time that a reproductive neuropeptide could simultaneously modulate both hormonal physiology and conscious sexual experience in humans.
Where KISS1R Exists Beyond the Hypothalamus
The brain effects of kisspeptin make anatomical sense. KISS1R is expressed not only in the hypothalamic GnRH neurons that control reproduction, but also in the amygdala, hippocampus, anterior cingulate cortex, and other limbic structures[5].
Tena-Sempere (2010) reviewed the emerging neuroanatomy and noted that kisspeptin neuron projections extend beyond the hypothalamus into regions involved in reward, emotion, and sexual behavior[6]. This distribution provides the biological basis for kisspeptin influencing sexual desire at the brain level, not just through downstream hormones.
Comninos and Dhillo (2017) synthesized the evidence and proposed that kisspeptin functions as a dual-purpose neuropeptide: one pathway controls GnRH and reproductive hormones; a parallel pathway modulates sexual and emotional brain processing through direct limbic KISS1R activation[5]. The two functions complement each other. The same peptide that prepares the body for reproduction (via GnRH/LH/FSH) simultaneously prepares the brain for sexual behavior.
Men With Low Sexual Desire (2023)
The healthy-volunteer data raised an obvious question: would kisspeptin work in men who actually have sexual dysfunction? Mills et al. (2023) tested this in a randomized, double-blind, placebo-controlled crossover trial in 32 men diagnosed with hypoactive sexual desire disorder (HSDD)[2].
Participants received kisspeptin-54 (1 nmol/kg/h) or matched placebo while undergoing fMRI during sexual video tasks and objective penile tumescence measurements.
Brain activity: Kisspeptin significantly modulated sexual brain processing compared to placebo, with a large effect size (Cohen d = 0.81, P = .003). During short erotic videos, kisspeptin enhanced activity in the left middle frontal gyrus and left anterior cingulate cortex while decreasing activity in the bilateral parahippocampus. During longer videos, kisspeptin enhanced right fusiform gyrus and bilateral visual cortex activation.
Penile tumescence: Kisspeptin produced significant increases in penile tumescence responses to sexual stimuli. The improvement reached up to 56% above placebo levels. This is a measurable physiological response, not just a self-report change.
No adverse events: Kisspeptin was well tolerated. No serious adverse events were reported. This is notable because the primary alternative for HSDD treatment, testosterone replacement, carries risks including erythrocytosis, prostate effects, and fertility suppression. Kisspeptin avoids all of these because it works through the body's own reproductive pathway.
The study was not designed to test chronic dosing or real-world efficacy. All measurements were taken during a single 75-minute infusion in a controlled laboratory setting.
Women With Low Sexual Desire (2022)
Mills et al. (2022) conducted a parallel randomized, double-blind, placebo-controlled crossover trial in women with HSDD[3]. This was the first study to investigate kisspeptin's effects on sexual brain processing in women with clinical sexual dysfunction.
The neuroimaging results differed from the male HSDD trial in important ways:
Reduced sexual aversion: Kisspeptin deactivated the left inferior frontal gyrus, a region associated with response inhibition and negative self-referential processing. The interpretation: kisspeptin reduced the neural brake that suppresses sexual engagement in women with HSDD.
Enhanced attraction processing: Kisspeptin activated the postcentral gyrus and supramarginal gyrus in response to erotic videos, regions involved in bodily awareness and sensory integration.
Feeling "sexy": Participants reported significantly increased ratings of feeling "sexy" during kisspeptin infusion compared to placebo. While self-report data is inherently limited, this aligns with the brain activation pattern showing reduced inhibitory processing.
The mechanism appears qualitatively different in women versus men. In men, kisspeptin primarily enhanced excitatory sexual processing (more activation in sexual-reward circuits). In women, it primarily reduced inhibitory processing (less activation in aversion and self-criticism circuits). Whether this reflects genuine sex differences in kisspeptin neurobiology or differences in the underlying pathology of HSDD between sexes remains unclear.
The deactivation pattern in women is consistent with models of female HSDD that emphasize excessive cognitive inhibition of sexual response rather than absent excitatory drive. In this framework, desire is not missing; it is being actively suppressed by prefrontal circuits associated with body image concerns, performance anxiety, or relational stress. Kisspeptin appears to quiet those inhibitory circuits, allowing the underlying sexual response system to function. This aligns with clinical observations that female HSDD is frequently context-dependent and influenced by psychological factors, while male HSDD more often correlates with hormonal deficiency or reduced excitatory neural drive.
Beyond Sex: Attraction and Olfaction (2020)
Comninos et al. (2020) investigated whether kisspeptin's effects extended beyond explicit sexual stimuli to subtler cues of attraction[4]. Using fMRI in 33 healthy heterosexual men, they tested kisspeptin's effects on brain responses to female olfactory cues (perfume), attractive female faces, and happy facial expressions.
Kisspeptin enhanced brain activity in the medial prefrontal cortex, posterior cingulate cortex, and amygdala in response to olfactory cues of attraction. It also enhanced responses to attractive faces in visual processing regions.
This study demonstrated that kisspeptin's brain effects are not limited to overt sexual stimuli. The peptide appears to modulate a broader "attraction network" that includes olfactory processing, facial attractiveness evaluation, and social-emotional responses. This is consistent with kisspeptin's role as an integrator: linking reproductive readiness (hormonal) with reproductive motivation (behavioral/neural).
The olfactory finding is particularly relevant because mate selection in humans, while less dependent on pheromones than in other mammals, still involves olfactory processing of body odor, pheromone-like compounds, and fragrance. Kisspeptin's ability to enhance neural responses to these cues suggests it may operate at a more fundamental level of attraction than conscious sexual desire.
How Kisspeptin Compares to Other Approaches
The kisspeptin approach to sexual dysfunction differs fundamentally from existing treatments. Bremelanotide (Vyleesi), the FDA-approved melanocortin agonist for female HSDD, also acts centrally on brain sexual circuits, but through melanocortin pathways (MC4R) rather than KISS1R. The two may target overlapping but distinct neural circuits.
Testosterone replacement for male HSDD raises testosterone levels directly, which can improve desire but suppresses the HPG axis, reducing fertility and potentially causing cardiovascular and hematologic side effects. Kisspeptin, by contrast, stimulates the HPG axis from the top, preserving or enhancing natural testosterone production while simultaneously activating limbic desire circuits. This dual mechanism (hormonal and neural) is unique to kisspeptin.
The challenge is delivery. Kisspeptin-54 requires IV infusion and has a half-life of approximately 28 minutes. No oral or subcutaneous formulation with sustained clinical effects is currently available. Developing longer-acting kisspeptin analogs or KISS1R agonists is an active area of pharmaceutical research, but no product is in late-stage clinical trials for HSDD as of 2026.
What the Evidence Does Not Show
All published kisspeptin-sexual-arousal studies involved single-session infusions in controlled laboratory settings. No study has tested repeated kisspeptin dosing for HSDD. The key unknowns include:
Several specific questions remain unanswered:
Translation to real-world desire: All brain activation data comes from controlled scanner environments. Whether the fMRI changes translate to meaningful improvements in sexual desire and behavior in daily life is untested.
Tachyphylaxis with repeated dosing: KISS1R desensitization occurs with continuous kisspeptin exposure (the same mechanism used therapeutically to suppress the reproductive axis). Whether pulsatile or intermittent dosing protocols could avoid desensitization while maintaining sexual effects is under investigation.
Age and hormonal status: All male studies enrolled relatively young men (mean age 30-40). Whether kisspeptin produces the same sexual brain effects in older men or in postmenopausal women with different baseline hormonal profiles is unknown. A study of kisspeptin in postmenopausal women with low sexual desire is registered in the UK.
HSDD heterogeneity: HSDD has multiple etiologies, including psychological, relational, hormonal, and neurological factors. Whether kisspeptin benefits all subtypes or primarily those with a neurobiological basis remains to be determined.
Interaction with kisspeptin's role in hypogonadism treatment: Men with hypogonadism often have low sexual desire. Whether kisspeptin's dual mechanism (restoring testosterone production AND directly activating sexual brain circuits) provides additive benefits in this population is a compelling but untested hypothesis.
The evidence supports a proof-of-concept that kisspeptin modulates human sexual brain processing. The path from proof-of-concept to approved therapy involves solving the delivery problem, demonstrating sustained efficacy, and testing in larger, more diverse populations.
The Bottom Line
Functional neuroimaging studies have demonstrated that kisspeptin-54 activates sexual and attraction brain circuits in both healthy volunteers and patients with HSDD. In men, kisspeptin enhanced sexual brain processing and increased penile tumescence by up to 56%. In women, kisspeptin reduced neural markers of sexual aversion and increased self-reported feelings of being "sexy." These effects occur within minutes through direct KISS1R activation in limbic brain regions, independently of hormonal changes. Kisspeptin offers a mechanistically distinct approach to sexual dysfunction that preserves the HPG axis, but all current evidence comes from single-session laboratory studies.